Addiction potential of phentermine prescribed during long-term treatment of obesity
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or phentermine drug craving in overweight, obese and weight loss maintenance patients. To investigate whether amphetamine-like withdrawal occurs after abrupt cessation of long-term phentermine treatment. Clinical intervention trial with interruption of phentermine treatment in long-term patients. 269 obese, overweight or formerly obese subjects (age: 20–88 years, BMI: 21–74 kg m−2) treated with phentermine long-term (LTP, N=117), 1.1–21.1 years, or short-term (ATP, N=152), 4–22 days, with phentermine doses of 18.75–112.5 (LTP) and 15–93.75 (ATP) mg per day. Module K of the Mini International Neuropsychiatric Interview modified for phentermine (MINI-SUD), Severity of Dependence Scale (SDS), 45-item Cocaine Craving Questionnaire-NOW (CCQ-NOW) modified for phentermine (PCQ-NOW), and Amphetamine Withdrawal Questionnaire (AWQ) modified for phentermine (PWQ). MINI-SUD interviews were negative for phentermine abuse or psychological dependence in all LTP patients. SDS examination scores were low for all LTP and ATP patients, indicating they were not psychologically dependent upon phentermine. PCQ-NOW scores were low for all LTP and ATP patients, indicating neither short-term nor long-term phentermine treatment had induced phentermine craving. Other than an increase in hunger or eating, amphetamine-like withdrawal symptoms did not occur upon abrupt phentermine cessation as measured by sequential PWQ scores. Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity. Phentermine treatment does not induce phentermine drug craving, a hallmark sign of addiction. Amphetamine-like withdrawal does not occur upon abrupt treatment cessation even at doses much higher than commonly recommended and after treatment durations of up to 21 years. Phentermine was approved by the US FDA in 1959 for short term use for obesity. It is the most commonly used anti-obesity drug on the US market and many US bariatric physicians use phentermine long term, ignoring the FDA guidelines that it be used for three months or less. Phentermine is not approved for use in Europe and some other countries around the world because of the fear of addiction, tachycardia, and elevated blood pressure. Actual objective assessments of phentermine, as compared to administrative opinions, have been rare. The article by Hendricks et al in this issue is one of the few available in the literature. The study is not optimally designed, but suggests that fears of addiction to phentermine are exaggerated. None of the 269 subjects who had been on phentermine for up to 21 years demonstrated any addictive behavior as assessed by questionnaire and physical examination. Prior studies in the literature in monkeys did not demonstrate significant addictive potential. However, phentermine has a reputation as a “street drug” and is sold in Europe for high prices. Since the combination of phentermine and topiramate has just been approved for long term use in the US, government sponsored, well controlled research into the long term use of generic phentermine is needed. There is no possibility that any private company will do long term research on this generic drug. Should the fears regarding phentermine be shown to be groundless, the positions of governments to ban phentermine should be reconsidered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
The clinical significance of drug craving
Tiffany, S. T., & Wray, J. M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06298.x · Cited by 556
The nature, time course and severity of methamphetamine withdrawal
McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01160.x · Cited by 458
Self-citationReliability and validity of the cocaine selective severity assessment
Kampman, K. M., Volpicelli, J. R., Mcginnis, D. E., Alterman, A. I., Weinrieb, R. M., D’Angelo, L., & Epperson, L. E. (1998) · Addictive Behaviors · doi:10.1016/s0306-4603(98)00011-2 · Cited by 272
Treatment for amphetamine withdrawal
Shoptaw, S. J., Kao, U., Heinzerling, K., & Ling, W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003021.pub2 · Cited by 120
How Physician Obesity Specialists Use Drugs to Treat Obesity
Hendricks, E. J., Rothman, R. B., & Greenway, F. L. (2009) · Obesity · doi:10.1038/oby.2009.69 · Cited by 97
Self-citationHendricks, E. J., Greenway, F. L., Westman, E. C., & Gupta, A. K. (2011) · Obesity · doi:10.1038/oby.2011.94 · Cited by 97
Self-citationKim, K. K., Cho, H.-J., Kang, H.-C., Youn, B.-B., & Lee, K.-R. (2006) · Yonsei Medical Journal · doi:10.3349/ymj.2006.47.5.614 · Cited by 88
Abuse liability assessment of atomoxetine in a drug-abusing population
Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M., & Allen, A. J. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.008 · Cited by 87
Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008
Samaranayake, N. R., Ong, K. L., Leung, R. Y. H., & Cheung, B. M. Y. (2012) · Annals of Epidemiology · doi:10.1016/j.annepidem.2012.01.001 · Cited by 52
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“There currently are no long-term data on safety or efficacy, although recent data on 269 patients treated long term with phentermine suggest that the addiction potential is low (131).”
BackgroundCurrent pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., Desai, J., Fitzpatrick, S. L., Horberg, M., Koebnick, C., et al. (2019) · Obesity · doi:10.1002/oby.22430 · Cited by 110
Off-label drugs for weight management
Hendricks, E. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s95299 · Cited by 82
“5 mg/day, did not induce phentermine cravings, and that abrupt cessation of long-term phentermine did not induce a stimulant withdrawal syndrome.(23,34) Assessment of drug “liking” is currently used as a measure of addiction potential.”
Self-citationApovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Metadata
- Authors
- Hendricks, E. J., Srisurapanont, M., Schmidt, S. L., Haggard, M., Souter, S., Mitchell, C. L., De Marco, D. G., Hendricks, M. J., Istratiy, Y., & Greenway, F. L.
- Venue
- International Journal of Obesity
- Published
- 2013-05-17
- Volume
- 38
- Issue
- 2
- Pages
- 292-298
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2071538269
- Cited by
- 67
- References
- 10
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.